CasNo.120014-06-4,99% up by HPLC Donepezil 120014-06-4,(120014-06-4) Suppliers

1 Kilogram	FOB Price: USD 100.0000

Min.Order :1 Kilogram
Purity: 99%
Payment Terms : L/C,D/A,D/P,T/T,

Keywords

120014-06-4 Donepezil 120014-06-4 Donepezil

Quick Details

Appearance:White powder
Application:API
PackAge:5kg/dru,m, 25kg/drum, or as your requirement
ProductionCapacity:10|Metric Ton|Year
Storage:Normal
Transportation:Room Temperature

Superiority:

Why is SINOWAY:

1) Specialized in pharmaceutical and healthcare industrial for 34 years.

2) ISO 9001:2015 & SGS audited supplier .

3) Accept various payment terms : T.T 30-60 days.

4) We have warehouse in USA with quickly shipment .

5) We can do different terms of FOB ,CIF/CIP ,DDP ...

Why choose us

1. best quality in your requirement
2. competitive price in china market
3. mature technical support
4. professional logistic support
5. full experience of large numbers containers loading in chinese sea port
6. fast shipment by reputed shipping line
7. packing with pallet as buyer's special request
8. best service after shipment with email !
9. cargoes together with container after-sales service available
10. full experience in export
11. raw materials from chinese origin

Details:

Product name	Donepezil
CAS No.	120014-06-4
Molecular Formula	C24H29NO3
Molecular Weight	379.49
Quality Standard	99% up by HPLC
Appearance	White powder

COA of Donepezil

ITEMS	SPECIFICATIONS	RESULTS
APPEARANCE	WHITE OR ALMOST WHITE CRYSTALLINE POWDER	CONFORMS
SOLUBILITY	TO MATCH WORKING STANDARD	CONFORMS
IDENTIFICATION	1) BY UV ABSORPTION,TO MATCH WORKING STANDARD 2) BY IR ABSORPTION,TO MATCH WORKING STANDARD	CONFORMS CONFORMS
MELTING POINT	86-90℃	87.5-88.5℃
RELATED SUBSTANCE
TOTAL	≤1.0%	0.14%
SINGLE IMPURITY (UNKNOWN)	≤0.80%	<0.8%
LOSS ON DRYING	≤1.0%	0.3%
RESIDUE ON IGNITION	≤0.10%	0.02%
HEAVY METAL	≤10 PPM	<10 PPM
ASSAY	≥99.0%	99.87%
CONCLUSION	CONFORMS TO THE ENTERPRISE STANDARD

Usage

Function of Donepezil

Donepezil is a potent, reversible, specific and noncompetitive acetylcholinesterase (AChE) inhibitor for the treatment of mild to moderate dementia.

In vitro studies:

Donepezil has a reversible and non-competitive inhibitory effect on AChE. It is 500-1000-fold more selective for AChE than for BuChE. Short- and long-term drug exposure to human SH-SY5Y neuroblastoma cells induces a concentration-dependent inhibition of cell proliferation independent of muscarinic or nicotinic receptor blockade and apoptosis. Donepezil reduces the number of cells in the S-G2/M phase of the cell cycle, increases the number in the G0/G1 phase, and reduces the expression of two cyclins in the G1/S and G2/M transitions: cyclinE and cyclinB. At the same time, it also increased the expression of the cell cycle repressor p21. In addition, donepezil increases action potential-dependent dopamine release and modulates nicotinic receptors in substantia nigra dopaminergic neurons.

In vivo studies:

Donepezil absorbs Chemicalbook slowly from the gastrointestinal tract in vivo, with a terminal half-life of 50-70 hours in young volunteers and more than 100 hours in elderly. After extensive hepatic metabolism, the parent compound is 93% bound to plasma proteins. Donepezil is metabolized in the liver by the cytochrome P450 system (CYP1A2-, CYP2D6-, CYP3A4-related enzymes). In animals, donepezil was unchanged in the brain and no metabolites were found in neural tissue. In plasma, urine and bile, most donepezil metabolites are O-glucuronides. After oral ingestion, peak plasma concentrations are reached within 3-5 hours, and its absorption is not affected by food. Donepezil has linear pharmacokinetics in the concentration range of 1-10 mg/day. 96% of circulating donepezil is protein bound.